Gynecologic Oncology | Interview with Stephanie Lheureux, MD, PhD

published 3 weeks ago by Dr Neil Love

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Lheureux on the following topic: Overall survival data with maintenance olaparib for platinum-sensitive recurrent OC with germline BRCA mutation from the Phase III SOLO-2 trial; optimal integration of PARP inhibitors in the treatment of recurrent disease (00:00) CME information and select publications

more episodes from Research To Practice | Oncology Videos